Information for the public

Amivantamab (Rybrevant) is not normally available on the NHS for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy in adults whose tumours have epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Your doctor should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your doctor decide when best to stop.

Information and support

The NHS website may be a good place to find out more.

These organisations can give you advice and support:

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4857-4

This page was last updated: